“BHI will strengthen Reckitt Benckiser’s global position in both health care and personal care,” said Bart Becht, CEO of Reckitt Benckiser.
“BHI will add three power brands to Reckitt Benckiser’s portfolio: Nurofen, Strepsils and Clearasil.
“Reckitt Benckiser will continue to invest behind BHI’s proven research and development and brand development capabilities and use its distribution capabilities to drive growth in new channels and new countries.”
The acquisiion remains subject to regulatory approval and rubber-stamping by Boots shareholders. However, Boots CEO Richard Baker has already signalled his approval of the move.